Science

Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker

Heidi Ko/LinkedIn

Mar 4, 2025, 11:22

Heidi Ko: Our latest mini-review on HER2 as a tumor-agnostic biomarker

Heidi Ko, Medical Director of Medical Affairs at Labcorp Drug Development, shared an article on LinkedIn:

“Excited to share that our latest mini-review on HER2 as a tumor-agnostic biomarker is now published in Frontiers in Oncology!

We delved into the evolving role of HER2 overexpression in various solid tumors and discussed how advancements in Antibody Drug Conjugates, particularly T-DXd, are transforming treatment strategies in solid malignancies.

We also addressed the challenges in HER2 testing across pan solid tumors and the potential of NGS and AI algorithms to enhance diagnostic accuracy.

Check out the full article here.”

From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates.

Authors: Heidi C Ko, et al.

More posts featuring Heidi Ko.

antibody biomarker cancer fight against cancer Frontiers in Oncology Global fight against cancer Heidi Ko HER2 Labcorp Drug Development OncoDaily Oncology T-Dxd

Dato' Dr Saunthari Somasundaram: I’m deeply honored to be elected as the next President-Elect of the NCD Alliance

Does Plastic Cause Cancer? Myths and Facts

TOPGEAR trial at ESTRO 2025: Preoperative Chemoradiotherapy for Resectable Gastric Cancer

Oncologist Near Me – Enrique Soto: A Leader in Geriatric Oncology and Global Cancer Care

Bianca Balti: The Supermodel’s Brave Battle with Ovarian Cancer